full-year guidance – Talk Bio

Actionable Insights Powered by AI

Eli Lilly Blows Past Revenue Benchmarks, Again Raises Full-Year Outlook

13 hours ago talkbio0Tagged earnings, eli lilly, exophthalmos producing substance, full-year guidance, Mounjaro, pharmaceutical innovation, Q3, revenue growth, Weight-Loss Agents, Zepbound

Eli Lilly; Q2 2025 earnings; Q3 2025 earnings; Mounjaro; Zepbound; weight-loss drugs; revenue growth; EPS; full-year guidance; pharmaceutical innovation